Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that its legal
team has been recognized with a Legal Media Group 2015 Life Sciences
Award as a “Hatch-Waxman Impact Case of the Year.” Acorda received the
award based on its initial district court victory related to
jurisdiction against the filer of an Abbreviated New Drug Application
(ANDA).
“We’re delighted by this recognition of our outstanding in-house legal
team, led by President, International and General Counsel Jane Wasman
and supported by expert external counsel, Kaye Scholer. This award
underscores our exceptional achievements in the area of patent
litigation,” said Ron Cohen, President and CEO of Acorda.
Legal Media Group selected Acorda Therapeutics v Mylan Pharmaceuticals
from among all of the Hatch-Waxman cases pending in the United States
over the last year. The case concerned Mylan’s motion to dismiss
Acorda’s ANDA case against it. Acorda won the motion based on
fundamental jurisdictional issues; Mylan has appealed. The decision in
this case may set a precedent regarding where brand companies can sue
generics in pending and future ANDA cases.
“We’re proud of the contribution we can make to the case law, as
defending legitimate intellectual property rights is critical to the
biotechnology industry’s ability to continue to invest in new,
innovative medicines,” said Jane Wasman, President, International and
General Counsel of Acorda.
The Acorda in-house Legal Department also was recognized by Corporate
Counsel in 2013 as one of the nation’s four “Best Legal Departments”
of the year.
About Acorda Therapeutics
Founded in 1995, Acorda
Therapeutics is a biotechnology company focused on developing
therapies that restore function and improve the lives of people with
neurological disorders.
Acorda markets three FDA-approved therapies, including AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg. The Company has one of
the leading pipelines in the industry of novel neurological therapies.
Acorda is currently developing a number of clinical and preclinical
stage therapies. This pipeline addresses a range of disorders including
post-stroke walking deficits, Parkinson’s disease, epilepsy, heart
failure, MS and spinal cord injury.
For more information, please visit the Company’s website at: www.acorda.com.
Forward Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be
considered forward-looking. These statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including the ability to realize the benefits anticipated from the
Civitas transaction and to successfully integrate Civitas' operations
into our operations; our ability to successfully market and sell Ampyra
in the U.S.; third party payers (including governmental agencies) may
not reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of unfavorable
results from future studies of Ampyra or from our other research and
development programs, including CVT-301, Plumiaz (diazepam) Nasal Spray,
or any other acquired or in-licensed programs; we may not be able to
complete development of, obtain regulatory approval for, or successfully
market CVT-301, Plumiaz, or any other products under development; we may
need to raise additional funds to finance our expanded operations and
may not be able to do so on acceptable terms; the occurrence of adverse
safety events with our products; delays in obtaining or failure to
obtain regulatory approval of or to successfully market Fampyra outside
of the U.S. and our dependence on our collaboration partner Biogen in
connection therewith; competition; failure to protect our intellectual
property, to defend against the intellectual property claims of others
or to obtain third party intellectual property licenses needed for the
commercialization of our products; and, failure to comply with
regulatory requirements could result in adverse action by regulatory
agencies.
These and other risks are described in greater detail in Acorda
Therapeutics' filings with the Securities and Exchange Commission.
Acorda may not actually achieve the goals or plans described in its
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in this
release are made only as of the date hereof, and Acorda disclaims any
intent or obligation to update any forward-looking statements as a
result of developments occurring after the date of this release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151002005126/en/
Copyright Business Wire 2015